Company intelligence / Profile preview
Crown Aesthetics
- Ownership
- Private
- Development stage
- Commercial
Overview
Crown Aesthetics has achieved FDA clearance for its flagship microneedling device SkinPen®, which was the first such device cleared by the FDA for facial acne scars. Its new product line BIOJUVE™, based on living microbe technology to optimize the skin biome, has shown clinically proven improvements in texture, tone, fine lines and wrinkles. The company’s PRP systems are widely used in aesthetic practices. Clinical results are supported by published pre-clinical and clinical research demonstrating efficacy and safety across their portfolio.
- Therapeutic areas
- Dermatology
- Modalities
- Device (microneedling devices)Platelet-rich plasma system (PRP)Living microbe-based skin biome therapy (biologic/device hybrid)Small molecule/peptide topical formulations (in some products)
- Industry
- Biotech
Drug pipeline
1 assetPartnerships
Beyond the preview
Go deeper on Crown Aesthetics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Crown Aesthetics.